# A Study of Standard Treatment +/- Apatinib in Extensive Stage Small Cell Lung Cancer

> **NCT03100955** · PHASE3 · UNKNOWN · sponsor: **Qingdao University** · enrollment: 120 (estimated)

## Conditions studied

- Progression Free Survival

## Interventions

- **DRUG:** cisplatin, etoposide
- **DRUG:** cisplatin, etoposide, apatinib

## Key facts

- **NCT ID:** NCT03100955
- **Lead sponsor:** Qingdao University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-03-01
- **Primary completion:** 2019-02-01
- **Final completion:** 2019-08-01
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2017-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03100955

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03100955, "A Study of Standard Treatment +/- Apatinib in Extensive Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03100955. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*